The company utilizes cutting-edge expertise in capsid discovery and deep neuropharmacology to overcome delivery challenges in gene therapy. Voyager's TRACER AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the limitations of conventional gene therapy vectors. Voyager has formed alliances with Pfizer, Novartis, and Neurocrine Biosciences, and has its own pipeline of preclinical programs targeting Parkinson's disease, Alzheimer's disease, and ALS.